Clinical Trials Sponsored by Roivant Sciences, Inc.

Total 1424 results

Kinevant Sciences GmbH
Roivant Sciences, Inc.

Completed

A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)

COVID-19

United States
Yale University
Roivant Sciences (HekaHeart)

Not yet recruiting

HekaHeart Phase 1 Proof of Concept (HekaHeart POC)

Heart Failure With Reduced Ejection Fraction

United States
Urovant Sciences GmbH

Completed

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Overactive Bladder

United States, Spain, Canada, Portugal, Poland, Belgium, Hungary, Lithuania
Urovant Sciences GmbH

Active, not recruiting

Composur: Study to Understand the Performance of Vibegron in Participants With Overactive Bladder (OAB)

Overactive Bladder

United States
Urovant Sciences GmbH

Completed

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Urovant Sciences GmbH

Completed

An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). (Empowur)

Overactive Bladder

United States
Urovant Sciences GmbH

Recruiting

A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC (KANGUROO)

Neurogenic Detrusor Overactivity

United States
Urovant Sciences GmbH

Completed

Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Overactive Bladder

United States, Poland
Urovant Sciences GmbH

Completed

URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence

Overactive Bladder With Urge Urinary Incontinence

United States
Urovant Sciences GmbH

Completed

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) (Empowur)

Overactive Bladder

United States, Latvia, Hungary, Canada, Lithuania, Poland
Children's Hospital Medical Center, Cincinnati
Cures Within Reach; Roivant Sciences, Inc.

Completed

Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder

Autism Spectrum Disorder

United States
Priovant Therapeutics, Inc.

Not yet recruiting

A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis

Dermatomyositis | Dermatomyositis, Adult Type
Priovant Therapeutics, Inc.

Recruiting

A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis (VALOR)

Dermatomyositis

United States, Belgium, Germany, Hungary, Israel, Italy, Netherlands, Portugal, Korea, Republic of, Bulgaria, Poland, Romania, Czechia, Taiwan, Chile, Mexico, Turkey, Serbia, Spain, United Kingdom, Canada
Priovant Therapeutics, Inc.

Not yet recruiting

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis (CLARITY) (CLARITY)

Uveitis | Uveitis, Posterior | Uveitis, Intermediate
Priovant Therapeutics, Inc.

Active, not recruiting

A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis (NEPTUNE)

Non-infectious Intermediate Uveitis | Non-infectious Posterior Uveitis | Non-infectious Pan Uveitis

United States
Urovant Sciences GmbH
Ion Channel Innovations

Terminated

Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity

Overactive Bladder

United States
Urovant Sciences GmbH
Ion Channel Innovations

Completed

Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer (OAB)

Overactive Bladder

United States
Halucenex Life Sciences Inc.
KGK Science Inc.

Active, not recruiting

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder

Post Traumatic Stress Disorder | Treatment Resistant Disorders

Canada
USANA Health Sciences
KGK Science Inc.

Completed

Effect of a MVM Dietary Supplement on Indices of Human Health

Metabolic Syndrome

Canada
Urovant Sciences GmbH
Dasman Diabetes Institute; Ion Channel Innovations

Completed

Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED

Erectile Dysfunction

Kuwait
SK Life Science, Inc.
PRA Health Sciences

Completed

Bioavailability and Food Effect Study of 3 Types of Carisbamate

Healthy Subjects

United States
IC-IT Sciences Inc.

Unknown

Comparison of the Natural Frequencies Technology Sleep Patches to Sham Patches During Sleep in the Home Environment

Sleep Disturbance

United States
Integrative Skin Science and Research
AgeLess Sciences Inc.

Active, not recruiting

The Effects of a Longevity Supplement on Aging and Photoaging

Photoaging

United States
Sight Sciences, Inc.

Not yet recruiting

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Pseudophakic Eyes (EVOLVE)

Primary Open Angle Glaucoma

United States
Kodiak Sciences Inc

Completed

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) (DAYLIGHT)

Wet Age-related Macular Degeneration

United States, Puerto Rico
Kodiak Sciences Inc

Terminated

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) (GLOW)

Non-proliferative Diabetic Retinopathy

United States, Latvia, Slovakia, Poland, Puerto Rico, Spain, Czechia
Kodiak Sciences Inc

Terminated

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) (GLIMMER)

Diabetic Macular Edema

United States, Israel, France, Italy, Hungary, Poland, Puerto Rico, Czechia
Dermavant Sciences, Inc.

Completed

A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis

Psoriasis

United States
Sight Sciences, Inc.

Active, not recruiting

Prospective, Randomized, Masked, Controlled Trial To Evaluate The Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)

Dry Eye | Meibomian Gland Dysfunction

United States
Sight Sciences, Inc.

Terminated

Study of OMNI Surgical System and iStent for Eyes With OAG (Trident)

Glaucoma, Open-Angle

Germany, Spain, United Kingdom
Sight Sciences, Inc.

Terminated

Randomized Study of the Safety and Effectiveness of the TearCare System for the Signs and Symptoms of Dry Eye Disease

Dry Eye Syndromes

United States
Rogers Sciences Inc.

Unknown

Safety Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds

Burn Wound

United States
Sight Sciences, Inc.

Unknown

Use of the OMNI® Surgical System in Combination With Cataract Extraction in Open Angle Glaucoma

Open Angle Glaucoma

United States
Sight Sciences, Inc.

Terminated

Randomized Study of the Safety and Effectiveness of the Sight Sciences VISCO™360 Viscosurgical System Versus SLT in Primary Open Angle Glaucoma (VISCO360 Study)

Open-Angle Glaucoma

United States
Hapten Sciences, Inc.

Completed

A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers

Contact Dermatitis

United States
MELA Sciences, Inc.

Completed

Does the Aid of MelaFind Affect Clinical Management Decisions

Melanoma

United States
5i Sciences, Inc.

Completed

Effectiveness of Continuous Negative External Pressure in Preventing Upper Airway Impairment During Routine Colonoscopy

Apnea | Airway Obstruction | Hypopnea

United States
Theraclone Sciences, Inc.

Unknown

Influenza Virus Challenge Study to Test Monoclonal Antibody TCN-032 as a Treatment for Influenza

Influenza

United Kingdom
Theraclone Sciences, Inc.

Completed

Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza

Influenza, Human

United States
MELA Sciences, Inc.

Completed

Survey Study - Sensitivity Comparison Between MelaFind and Physician Group

Melanoma
Larada Sciences, Inc.

Completed

Control of Head Lice Infestations in Children and Adults

Pediculosis

United States
Kodiak Sciences Inc

Recruiting

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) (GLOW2)

Non-proliferative Diabetic Retinopathy

United States, Puerto Rico
Translational Sciences, Inc.

Recruiting

Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial (NAIL-IT)

Pulmonary Embolism

United States
Kodiak Sciences Inc

Completed

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) (BEACON)

Macular Edema | Retinal Vein Occlusion

Spain, United States, Latvia, Israel, France, Italy, Hungary, Germany, Poland, Slovakia, Puerto Rico, Czechia
Cassava Sciences, Inc.

Enrolling by invitation

Open-label Extension for Phase 3 Clinical Trials of Simufilam

Alzheimer Disease

United States, Canada, Puerto Rico
Cassava Sciences, Inc.

Completed

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects

Metabolism | Absorption | Excretion

United States
Dermavant Sciences, Inc.

Completed

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Cassava Sciences, Inc.

Active, not recruiting

Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Canada
Kodiak Sciences Inc

Terminated

A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) (GLEAM)

Diabetic Macular Edema

United States, Latvia, Spain, Germany, Italy, Slovakia, Hungary, Puerto Rico
Dermavant Sciences, Inc.

Completed

Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

Atopic Dermatitis

United States, Canada

3

Subscribe